← All trials
NCT02735070
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 1, 2016
- Primary completion
- Mar 1, 2017
- Completion date
- Mar 1, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 366
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Brainfarma Industria Química e Farmacêutica S/ALead sponsor
- Pesquisare Saude S/S LtdaOverall official - principal investigator
- CliniliveOverall official - principal investigator
- CTD Dor Clinica de Diagnostico e Terapia da Dor LtdaOverall official - principal investigator
- Techtrials Pesquisa e Tecnologia LtdaCollaborator
- PharmagenixCollaborator
- Hospital Nipo-BrasileiroOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.